CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: While both groups reported that the generated CML-iPSC lines were resistant to the tyrosine kinase inhibitor imatinib, which is used to treat CML patients, Bedel et al. (39) found that CD34+ hematopoietic progenitors obtained from their patient's CML-iPSCs were partially sensitive to imatinib and Kumano et al. (57) found imatinib-sensitivity in CML-iPSC derived CD34− hematopoietic cells but not CD34+ hematopoietic progenitors, which recapitulated the pathophysiological feature of initial CML of that patient.